Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06027-w ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yiyan Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soo…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the National Clinical Research Center for Hematologic Disease.
Abstract (Originalsprache)
Olverembatinib is a novel orally administered third-generation tyrosine kinase inhibitor (TKI) with definitive responses in T315I-mutant chronic myeloid leukemia (CML) patients. However, its value in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) remained unclarified. In this multiple-center study, 20 patients with de novo Ph + ALL were treated with olverembatinib-based regimens as frontline therapy. All patients acquired complete remission (CR) after induction. 85% of patients achieved complete molecular response (CMR) within three months, contributed mainly by the addition of blinatumomab. A total of 45% of patients experienced mild hematological treatment-related adverse events (TRAEs). Olverembatinib-based treatment led to promising outcomes in de novo Ph + ALL patients but warranted further studies to investigate the best-combined strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, People's Republic of China.
- Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People's Republic of China.
- Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, People's Republic of China. chensuning@suda.e…
- Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People's Republic of China. chensuning@suda.edu.cn.
Förderung
- National Natural Science Foundation of China
- the National Clinical Research Center for Hematologic Disease
Zitieren
APA
Zhu, Y., Huang, J., Wang, Y., Han, Y., Xue, S., Yang, Y., Zhu, Y., Cai, W., & Chen, S. (2024). Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-06027-w
Vancouver
Zhu Y, Huang J, Wang Y, Han Y, Xue S, Yang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-06027-w
BibTeX
@article{Zhu2024,
author = {Zhu, Yiyan and Huang, Jiayi and Wang, Ying and Han, Yue and Xue, Shengli and Yang, Yonggong and Zhu, Yu and Cai, Wenzhi and Chen, Suning},
title = {Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06027-w}
}
EUVIMED